FDA Public Meeting Report on “Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications”

2018 ◽  
Vol 58 (12) ◽  
pp. 1655-1665 ◽  
Author(s):  
Mohammad Akbar ◽  
Erin Berry-Bibee ◽  
Diana L. Blithe ◽  
Ruth S. Day ◽  
Alison Edelman ◽  
...  
Keyword(s):  
Public Health ◽  
Drug Development ◽  
Drug Interactions ◽  
Hormonal Contraceptives ◽  
Meeting Report ◽  
Public Meeting

scholarly journals Prevalence of Drug–Drug Interactions with Hormonal Contraceptives and Antiretrovirals in Women Living with HIV

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S662-S662
Author(s):  
Milena M McLaughlin ◽  
Ashley Jensen ◽  
Susan Cohn ◽  
Kristin Darin
Keyword(s):  
Drug Interactions ◽  
Hormonal Contraceptives ◽  
Women Living With Hiv ◽  
Living With Hiv

scholarly journals Current Antimycotics, New Prospects, and Future Approaches to Antifungal Therapy

Antibiotics ◽  
2020 ◽  
Vol 9 (8) ◽  
pp. 445 ◽  
Author(s):  
Gina Wall ◽  
Jose L. Lopez-Ribot
Keyword(s):  
Drug Development ◽  
Drug Interactions ◽  
Fungal Infections ◽  
Mortality Rates ◽  
Clinical Development ◽  
Antifungal Drugs ◽  
High Morbidity ◽  
Eukaryotic Organisms ◽  
Emergence Of Resistance ◽  
Compromised Patients

Fungal infections represent an increasing threat to a growing number of immune- and medically compromised patients. Fungi are eukaryotic organisms and, as such, there is a limited number of selective targets that can be exploited for antifungal drug development. This has also resulted in a very restricted number of antifungal drugs that are clinically available for the treatment of invasive fungal infections at the present time—polyenes, azoles, echinocandins, and flucytosine. Moreover, the utility of available antifungals is limited by toxicity, drug interactions and the emergence of resistance, which contribute to high morbidity and mortality rates. This review will present a brief summary on the landscape of current antifungals and those at different stages of clinical development. We will also briefly touch upon potential new targets and opportunities for novel antifungal strategies to combat the threat of fungal infections.

Use of biomarkers to improve immunosuppressive drug development and outcomes in renal organ transplantation: A meeting report

2020 ◽  
Vol 20 (6) ◽  
pp. 1495-1502
Author(s):  
Roslyn B. Mannon ◽  
Randall E. Morris ◽  
Michael Abecassis ◽  
David Axelrod ◽  
Shukal Bala ◽  
...  
Keyword(s):  
Drug Development ◽  
Organ Transplantation ◽  
Immunosuppressive Drug ◽  
Meeting Report
Sign in / Sign up

Export Citation Format

Share Document